These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8614363)

  • 1. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
    Fountzilas G; Gossios K; Zisiadis A; Svarna E; Skarlos D; Pavlidis N
    Med Pediatr Oncol; 1996 May; 26(5):305-17. PubMed ID: 8614363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.
    Van Halteren HK; Roumen RM; Coebergh JW; Croiset van Uchelen FA; Keuning JJ; Vreugdenhil G
    Anticancer Res; 1999; 19(4C):3447-9. PubMed ID: 10629633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Yuste AL; Aparicio J; Segura A; López-Tendero P; Gironés R; Pérez-Fidalgo JA; Díaz R; Calderero V
    Clin Colorectal Cancer; 2003 Feb; 2(4):231-4. PubMed ID: 12620142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
    Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
    Assersohn L; Norman A; Cunningham D; Benepal T; Ross PJ; Oates J
    Br J Cancer; 1999 Apr; 79(11-12):1800-5. PubMed ID: 10206296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
    J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
    Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
    Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
    Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
    J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many?
    Yan DB; Clingan P; Morris DL
    Cancer; 2003 Jul; 98(2):320-30. PubMed ID: 12872352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
    Wang WS; Chen PM; Chiou TJ; Liu JH; Fan FS; Lin TC; Jiang JK; Yang SH; Yen CC; Wang HS; Lin JK
    Hepatogastroenterology; 2000; 47(36):1590-4. PubMed ID: 11149009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
    Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
    J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
    Popov IP; Milicevic M; Kecmanovic D; Tomasevic Z; Radosevic-Jelic Lj; Borojevic N; Micev MT; Kezic I
    J Exp Clin Cancer Res; 2006 Sep; 25(3):313-9. PubMed ID: 17167970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.